The Single Best Way to Deliver

UNITHER Pharmaceuticals develops and manufactures pharmaceuticals products on behalf of its customers.

How does Unither differentiate itself?

  • By specializing in certain pharmaceutical forms, in particular sterile single unit dose
  • By offering turnkey products to its customers, that they will be able to sell under their own brand.

UNITHER Pharmaceuticals, worldwide leader in single unit doses, is one of France's leading pharmaceutical manufacturers with a turnover of nearly € 300 million in 2018. The Group has 4 production plants in France, 1 in the United States, 1 in Brazil and 1 development center in Bordeaux.

Our deep understanding of patient needs and our experience in product development and process implementation ensures the best conditions for our customers’ market success.

Our Vision and Mission

Our vision is to make affordable and user-friendly products that everyone in the world can use to improve their lives.

To fulfill this vision, we constantly strive to provide our customers with innovative, competitive and sustainable solutions, while always taking patient needs into account. With our experience and technology, we can assist our customers at any and every stage of the development process to help ensure the product’s success.

If the patient is offered an affordable product that they prefer, they will be happy, our customer will be happy, and we will be happy. We are deeply committed to the success of our customers.

Our Values

We live and work every day to promote our core values of Innovation, Respect, Responsibility, Courage, and Trust.

Respect for our core values guarantees an ethic of collaboration between Unither and our customers.

 

Timeline

The Beginning

Created with the purchase of a small Sanofi pharmaceutical manufacturing plant in Amiens (France), Unither grew rapidly through sterile unit dose manufacture using Blow-Fill-Seal technology (BFS), and a unique pricing structure.
1993

Specialized Manufacturing

Implemented the strategy of a specialized focus on sterile unit dose manufacturing.
1995

Unither goes International

Expanded international markets with exports to Europe and development of commercial, operational and regulatory capacity for international customers.
1997

Continued Development

Unither joined forces with a financial partner to accelerate the group's development, particularly through external growth.
2000

Growth & Expansion

Unither acquired a second manufacturing site in Coutances (France) for its sterile unit dose manufacture.
2002

Product & Service Diversification

Diversified with effervescent products, non-sterile liquid forms, and pharmaceutical development with the acquisition of Créapharm in 2005.
2005

Additional Specialized Manufacturing

The launch of Unistick® stick-pack for liquid and paste forms marked a major advance for our ability to offer unique unit dose solutions.
2006

Capacity Expansion

Unither purchased the Colomiers (France) site from Sanofi-Aventis, gaining a competitive platform for the production of high volumes of Unistick®.
2009

Another Cutting-Edge Product

Introduced Uniflash®, a new, patented, BTM (Buccal Trans-Mucous) drug delivery system that is comparable to an intravenous solution.
2010

International Expansion

In response to customer needs, we opened commercial offices in Brazil, a growing pharmaceutical market with a huge potential for drug products.
2011

Entering the US

With the acquisition of a manufacturing plant in Rochester (USA) from UCB, Unither expanded once again. This was a major turning point; directly entering the North American market with tablets, hard capsules, liquid forms, BFS and liquid-stick-pack.
2013

Acquisition of Barretos Plant

With the acquisition of a manufacturing plant in Barretos we strengthened our presence in Brazil.
2015

A new Cutting-Edge Product: ODX

The orodispersible dosage forms have been developed to improve swallowing of oral dosage forms particularly for patients with dysphagia such as geriatric and pediatric population.
2016

Entering Asia

Opening of a Chinese subsidiary in Wuhan in order to bring innovative technologies to Chinese pharmaceutical laboratories and patients
2016